Florian Krismer
A5054318770- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Botulinum Toxin and Related Neurological Disorders
- Neurological diseases and metabolism
- Advanced Neuroimaging Techniques and Applications
- Nuclear Receptors and Signaling
- Alzheimer's disease research and treatments
- Mitochondrial Function and Pathology
- Parkinson's Disease and Spinal Disorders
- Restless Legs Syndrome Research
- Cannabis and Cannabinoid Research
- Olfactory and Sensory Function Studies
- Cardiovascular Syncope and Autonomic Disorders
- Cerebral Palsy and Movement Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Liver Disease and Transplantation
- Nutrition and Health in Aging
- Liver Disease Diagnosis and Treatment
- Attention Deficit Hyperactivity Disorder
- Ginkgo biloba and Cashew Applications
- Neurotransmitter Receptor Influence on Behavior
- Biochemical Analysis and Sensing Techniques
- RNA regulation and disease
- Heart Rate Variability and Autonomic Control
Universität Innsbruck
2016-2025
Innsbruck Medical University
2016-2025
John Wiley & Sons (United States)
2020-2024
The Kinghorn Cancer Centre
2017
Neuroscience Research Australia
2017
Mayo Clinic in Florida
2017
National Institute of Neurological Disorders and Stroke
2017
The University of Sydney
2017
Barrow Neurological Institute
2017
ETH Zurich
2011
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity limited variant syndromes with presentations other than Richardson's syndrome. Objective: We aimed to provide an evidence- consensus-based revision clinical criteria PSP. Methods: searched PubMed, Cochrane, Medline, PSYCInfo databases articles English...
An efficiency-optimized modulation scheme and design method are developed for an existing hardware prototype of a bidirectional dual active bridge (DAB) dc/dc converter. The DAB being considered is used automotive application made up high-voltage port with voltage V <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub> , 240 ≤ 450 V, low-voltage xmlns:xlink="http://www.w3.org/1999/xlink">2</sub> 11 16 V; the rated output power 2 kW. A much...
BackgroundMultiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder that characterised by autonomic failure, cerebellar ataxia, parkinsonism in various combinations. Here we present the final analysis of prospective multicentre study European MSA Study Group to investigate natural history MSA.MethodsPatients with clinical diagnosis were recruited followed up clinically for 2 years. Vital status was ascertained years after completion. Disease...
ABSTRACT Background Dorsolateral nigral hyperintensity on iron‐sensitive magnetic resonance imaging (MRI) sequences seems to be a typical finding in Parkinson's disease (PD), but most studies have involved small samples and had heterogeneous control populations. Objectives The objective of this study was perform meta‐analysis dorsolateral as an marker for PD. Methods methods included systematic literature search hierarchical summary receiver operating characteristics curve approach. Results...
Absence of a hyperintense, ovoid area within the dorsolateral border otherwise hypointense pars compacta substantia nigra (referred to as nigral hyperintensity) on iron-sensitive high-field magnetic resonance imaging sequences seems be typical finding for patients with Parkinson's disease (PD).This study was undertaken evaluate diagnostic value hyperintensity in cohort neurodegenerative parkinsonism including PD, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) well...
The objective of this study was to assess the efficacy and safety nabilone, a synthetic tetrahydrocannabinol analogue, as treatment for non-motor symptoms (NMS) in Parkinson's disease (PD).This phase II placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal trial conducted at Medical University Innsbruck. A random sample 47 patients with PD stable motor disturbing NMS defined by score ≥4 points on Movement Disorder Society - Unified Rating Scale-I...
There is a critical need to develop valid, non-invasive biomarkers for Parkinsonian syndromes. The current 17-site, international study assesses whether diffusion MRI (dMRI) can distinguish between
<b><i>Background:</i></b> Sarcopenia and frailty are found in up to one-third of the general elderly population. Both associated with major adverse health outcomes such as nursing home placement, disability, decreased quality life, death. Data on frequency both syndromes Parkinson’s disease (PD), however, very limited.<b><i> Objective:</i></b> We aimed screen for sarcopenia PD patients assess potential associations geriatric demographic...
Highlights•Generation of a foundational genomic resource in multiple system atrophy•GWAS identifies novel risk loci at GAB1, lnc-LRRC49-3, TENM2, and RABGEF1•Functional genomics implicates USP38-DT, KCTD7, lnc-KCTD7-2 within these loci•Gene-burden analysis nominal enrichment rare missense mutations KCTD7SummaryMultiple atrophy (MSA) is an adult-onset, sporadic synucleinopathy characterized by parkinsonism, cerebellar ataxia, dysautonomia. The genetic architecture MSA poorly understood,...
Abstract Introduction The aim of this German national guideline is to optimize the clinical care patients with Parkinson's disease (PD) in terms diagnostics, drug and surgical treatment care. Summary or definition topic This guidance was prepared for Society Neurology (DGN) collaboration Austrian (ÖGN) Swiss Neurological (SNG) German-speaking countries. guidelines diagnosis PD have been revised by a expert group commission DGN at S2k level. main objective these regarding diagnosis, including...
Abstract Background Imaging markers that are sensitive to parkinsonism across multiple sites critically needed for clinical trials. The objective of this study was evaluate changes in the substantia nigra using single‐ and bi‐tensor models diffusion magnetic resonance imaging PD, MSA, PSP. Methods cohort (n = 425) included 107 healthy controls 184 63 71 PSP patients from 3 movement disorder centers. Bi‐tensor free water, free‐water‐corrected fractional anisotropy, mean diffusivity,...
IntroductionThe hummingbird sign and the morning glory flower sign, reflecting midbrain pathology on MRI, have previously been shown to separate patients with progressive supranuclear palsy (PSP) from those Parkinson's disease (PD) multiple system atrophy (MSA). The aim of present study was determine diagnostic accuracy reproducibility visual assessment patterns in a large cohort neurodegenerative parkinsonism.MethodsRetrospective analysis T1-weighted MRI parkinsonism healthy controls who...
Differentiating progressive supranuclear palsy-parkinsonism (PSP-P) from Parkinson's disease (PD) is clinically challenging.This study aimed to develop an automated Magnetic Resonance Parkinsonism Index 2.0 (MRPI 2.0) algorithm distinguish PSP-P PD and validate its diagnostic performance in two large independent cohorts.We enrolled 676 participants: a training cohort (n = 346; 43 PSP-P, 194 PD, 109 control subjects) our center testing 330; 62 171 97 international research group. We developed...
Impulse control disorders (ICD), psychosis and delirium are part of the spectrum behavioural changes associated with Parkinson's disease (PD). The diagnostic therapeutic management these rather complex neuropsychiatric conditions has been updated in clinical guideline by German Society Neurology (DGN).